Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ZD6474--clinical experience to date.

J V Heymach1

  • 1Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. John_Heymach@dfci.harvard.edu

British Journal of Cancer
|June 2, 2005
PubMed
Summary

ZD6474, a novel agent, targets tumor growth by inhibiting vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) pathways. Ongoing Phase II trials evaluate its efficacy in non-small-cell lung cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer.

ESMO open·2026
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tumor growth is driven by angiogenesis and cell proliferation.
  • Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor (EGF) are key signaling molecules.
  • Targeted therapies offer new approaches to cancer treatment.

Purpose of the Study:

  • To evaluate the safety and efficacy of ZD6474, a dual inhibitor of VEGF and EGF pathways.
  • To assess ZD6474 in monotherapy and combination regimens for non-small-cell lung cancer (NSCLC).
  • To explore optimal clinical trial designs for molecularly targeted agents.

Main Methods:

  • Phase I clinical evaluation of ZD6474 for safety and tolerability.
  • Phase II randomized trials in NSCLC patients comparing ZD6474 monotherapy vs. gefitinib.
  • Phase II trials evaluating ZD6474 in combination with chemotherapy (carboplatin/paclitaxel or docetaxel).

Main Results:

  • Phase I showed ZD6474 to be generally well tolerated with suitable pharmacokinetics for daily oral dosing.
  • Phase II trials are ongoing, assessing ZD6474 in various NSCLC patient populations and treatment settings.
  • Efficacy data from ongoing trials will determine ZD6474's role in NSCLC treatment.

Conclusions:

  • ZD6474 demonstrates a promising safety profile and targets critical tumor growth pathways.
  • Ongoing clinical trials will elucidate the therapeutic potential of ZD6474 in NSCLC.
  • The development of ZD6474 highlights the need for adaptive clinical trial designs for targeted cancer therapies.

Related Experiment Videos